IP Verse

Pfizer, Inc. vs Biogen, Inc.

The detailed information for PTAB case with proceeding number IPR2017-01167 filed by Pfizer, Inc. against Biogen, Inc. on Apr 27, 2017. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number: IPR2017-01167
Filing Date: Apr 27, 2017
Petitioner: Pfizer, Inc.
Respondent: Biogen, Inc.
Status: Institution Denied
Respondent Application Number: 09628187
Respondent Tech Center: 1600
Respondent Patent Number: 8557244
Institution Decision Date: Nov 6, 2017

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.

Show Exhibit Documents

Document Name	Filing Date	Category	Filing Party
Alert me when new update on this case
Notice of Refund	Apr 5, 2018	PAPER	BOARD
MOTION FOR REFUND OF POST-INSTITUTION FEE	Mar 23, 2018	PAPER	PETITIONER
Decision Denying Petitioner's Request for Rehearing	Mar 22, 2018	PAPER	BOARD
Petitioner's Updated Mandatory Notice	Jan 31, 2018	PAPER	PETITIONER
Patent Owner's Updated Mandatory Notice	Dec 27, 2017	PAPER	PATENT OWNER
Petitioner's Request for Rehearing	Dec 5, 2017	PAPER	PETITIONER
Trial Instituted Document	Nov 6, 2017	PAPER	BOARD
Ex 2017 McLaughlin, Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy	Aug 8, 2017	EXHIBIT	PATENT OWNER
Ex 2001 S. Al Ismail, Combination Chemotherapy Including Epirubicin	Aug 8, 2017	EXHIBIT	PATENT OWNER
Ex 2004 Armitage, Treatment of Non-Hodgkin's Lymphoma	Aug 8, 2017	EXHIBIT	PATENT OWNER
Ex 2005 Ford, Immunotherapeutic Approaches to Treatment of B-Cell Neoplasms	Aug 8, 2017	EXHIBIT	PATENT OWNER
Ex 2008 U.S. Patent No. 8,329,172 issued to Grillo-Lopez, Dec. 11, 2012	Aug 8, 2017	EXHIBIT	PATENT OWNER
Ex 2009 Meyer, Phase I Trial of Standard and Cyclophosphamide Dose-Escalated CHO	Aug 8, 2017	EXHIBIT	PATENT OWNER
Ex 2010 Piro, RITUXAN: Interim analysis of a phase II study	Aug 8, 2017	EXHIBIT	PATENT OWNER
Ex 2011 Sonneveld, Comparison of Doxorubicin and Mitoxantrone	Aug 8, 2017	EXHIBIT	PATENT OWNER
Ex 2012 Excerpts from Appl. No. 09/628,187 file history	Aug 8, 2017	EXHIBIT	PATENT OWNER
Ex 2013 NCI Cancer Toxicity Criterial Manual	Aug 8, 2017	EXHIBIT	PATENT OWNER
Ex 2015 Feenstra, Drug-Induced Heart Failure	Aug 8, 2017	EXHIBIT	PATENT OWNER
Ex 2016 Sriskandan, Aggressive management of doxorubicin-induced cardiomyopathy	Aug 8, 2017	EXHIBIT	PATENT OWNER
Patent Owner's Exhibit List	Aug 8, 2017	PAPER	PATENT OWNER
Patent Owner's Preliminary Response	Aug 8, 2017	PAPER	PATENT OWNER
Patent Owner's Mandatory Notice	May 18, 2017	PAPER	PATENT OWNER
Power of Attorney	May 18, 2017	PAPER	PATENT OWNER
Notice of Accord Filing Date	May 8, 2017	PAPER	BOARD
Pat. No. 8,557,244	Apr 27, 2017	EXHIBIT	PETITIONER
McNeil	Apr 27, 2017	EXHIBIT	PETITIONER
1997 Rituxan Label	Apr 27, 2017	EXHIBIT	PETITIONER
Coiffier	Apr 27, 2017	EXHIBIT	PETITIONER
Campbell	Apr 27, 2017	EXHIBIT	PETITIONER
Skarin	Apr 27, 2017	EXHIBIT	PETITIONER
Grossbard	Apr 27, 2017	EXHIBIT	PETITIONER
Link	Apr 27, 2017	EXHIBIT	PETITIONER
Howard Ozer Declaration	Apr 27, 2017	EXHIBIT	PETITIONER
Davis	Apr 27, 2017	EXHIBIT	PETITIONER
Armitage II	Apr 27, 2017	EXHIBIT	PETITIONER
Shipp	Apr 27, 2017	EXHIBIT	PETITIONER
Martelli	Apr 27, 2017	EXHIBIT	PETITIONER
Hiddemann II	Apr 27, 2017	EXHIBIT	PETITIONER
Hiddemann III	Apr 27, 2017	EXHIBIT	PETITIONER
Foon	Apr 27, 2017	EXHIBIT	PETITIONER
Armitage I	Apr 27, 2017	EXHIBIT	PETITIONER
2012.11.07 Notice of Allowability	Apr 27, 2017	EXHIBIT	PETITIONER
Tsai	Apr 27, 2017	EXHIBIT	PETITIONER
Rituxan 1999 PDR	Apr 27, 2017	EXHIBIT	PETITIONER
2012.06.26 Non-Final Office Action	Apr 27, 2017	EXHIBIT	PETITIONER
2012.08.20 Amendment and Response to Non-Final Office Action	Apr 27, 2017	EXHIBIT	PETITIONER
Scott Bennett Declaration_Part 2	Apr 27, 2017	EXHIBIT	PETITIONER
Scott Bennett Declaration_Part 1	Apr 27, 2017	EXHIBIT	PETITIONER
POA on behalf of Pfizer Inc	Apr 27, 2017	PAPER	PETITIONER
PETITION FOR INTER PARTES REVIEW	Apr 27, 2017	PAPER	PETITIONER